Parthenon Therapeutics, a Cambridge, Mass.-based biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment, raised $65m in Series A financing.
The round was led by Northpond Ventures, Pfizer Ventures, and Taiho Ventures with participation from Section 32, Breakout Ventures, funds managed by Tekla Capital Management LLC, Creacion Ventures, KdT Ventures, Park West Asset Management LLC, and Alexandria Venture Investments.
The company plans to use the funds to develop new therapies that target immune exclusion in tumors.
Led by Laurent Audoly, Ph.D., co-founder and Chief Executive Officer, Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.
The team also includes:
- C. Glenn Begley, M.D., Ph.D., Parthenon’s co-founder and Head of Drug Discovery,
- Guy Travis Clifton, M.D., co-founder and Chief Medical Officer, and
- Olga Granaturova, MBA, co-founder and Chief Operating Officer.
FinSMEs
03/11/2021